Literature DB >> 29937418

Optimized Cholesterol-siRNA Chemistry Improves Productive Loading onto Extracellular Vesicles.

Reka Agnes Haraszti1, Rachael Miller2, Marie-Cecile Didiot1, Annabelle Biscans1, Julia F Alterman1, Matthew R Hassler1, Loic Roux1, Dimas Echeverria1, Ellen Sapp3, Marian DiFiglia3, Neil Aronin4, Anastasia Khvorova5.   

Abstract

Extracellular vesicles are promising delivery vesicles for therapeutic RNAs. Small interfering RNA (siRNA) conjugation to cholesterol enables efficient and reproducible loading of extracellular vesicles with the therapeutic cargo. siRNAs are typically chemically modified to fit an application. However, siRNA chemical modification pattern has not been specifically optimized for extracellular vesicle-mediated delivery. Here we used cholesterol-conjugated, hydrophobically modified asymmetric siRNAs (hsiRNAs) to evaluate the effect of backbone, 5'-phosphate, and linker chemical modifications on productive hsiRNA loading onto extracellular vesicles. hsiRNAs with a combination of 5'-(E)-vinylphosphonate and alternating 2'-fluoro and 2'-O-methyl backbone modifications outperformed previously used partially modified siRNAs in extracellular vesicle-mediated Huntingtin silencing in neurons. Between two commercially available linkers (triethyl glycol [TEG] and 2-aminobutyl-1-3-propanediol [C7]) widely used to attach cholesterol to siRNAs, TEG is preferred compared to C7 for productive exosomal loading. Destabilization of the linker completely abolished silencing activity of loaded extracellular vesicles. The loading of cholesterol-conjugated siRNAs was saturated at ∼3,000 siRNA copies per extracellular vesicle. Overloading impaired the silencing activity of extracellular vesicles. The data reported here provide an optimization scheme for the successful use of hydrophobic modification as a strategy for productive loading of RNA cargo onto extracellular vesicles.
Copyright © 2018 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  RNA therapy; chemical modification; exosomes; extracellular vesicles; nanovesicles; oligonucleotides; siRNA

Mesh:

Substances:

Year:  2018        PMID: 29937418      PMCID: PMC6094392          DOI: 10.1016/j.ymthe.2018.05.024

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  54 in total

Review 1.  Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides.

Authors:  Richard S Geary; Daniel Norris; Rosie Yu; C Frank Bennett
Journal:  Adv Drug Deliv Rev       Date:  2015-02-07       Impact factor: 15.470

2.  Novel hydrophobically modified asymmetric RNAi compounds (sd-rxRNA) demonstrate robust efficacy in the eye.

Authors:  Michael Byrne; Radouil Tzekov; Yi Wang; Amanda Rodgers; James Cardia; Glenna Ford; Katherine Holton; Lakshmipathi Pandarinathan; Jennifer Lapierre; William Stanney; Karen Bulock; Sharon Shaw; Lyn Libertine; Kevin Fettes; Anastasia Khvorova; Shalesh Kaushal; Pamela Pavco
Journal:  J Ocul Pharmacol Ther       Date:  2013-11-01       Impact factor: 2.671

3.  Mesenchymal stem cells deliver exogenous miRNAs to neural cells and induce their differentiation and glutamate transporter expression.

Authors:  Hae Kyung Lee; Susan Finniss; Simona Cazacu; Cunli Xiang; Chaya Brodie
Journal:  Stem Cells Dev       Date:  2014-09-22       Impact factor: 3.272

4.  Visualization of self-delivering hydrophobically modified siRNA cellular internalization.

Authors:  Socheata Ly; Deanna M Navaroli; Marie-Cécile Didiot; James Cardia; Lakshmipathi Pandarinathan; Julia F Alterman; Kevin Fogarty; Clive Standley; Lawrence M Lifshitz; Karl D Bellve; Matthieu Prot; Dimas Echeverria; Silvia Corvera; Anastasia Khvorova
Journal:  Nucleic Acids Res       Date:  2016-11-28       Impact factor: 16.971

5.  Nucleic acid loading and fluorescent labeling of isolated extracellular vesicles requires adequate purification.

Authors:  Stephan Stremersch; Toon Brans; Kevin Braeckmans; Stefaan De Smedt; Koen Raemdonck
Journal:  Int J Pharm       Date:  2017-10-12       Impact factor: 5.875

6.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Authors:  Jürgen Soutschek; Akin Akinc; Birgit Bramlage; Klaus Charisse; Rainer Constien; Mary Donoghue; Sayda Elbashir; Anke Geick; Philipp Hadwiger; Jens Harborth; Matthias John; Venkitasamy Kesavan; Gary Lavine; Rajendra K Pandey; Timothy Racie; Kallanthottathil G Rajeev; Ingo Röhl; Ivanka Toudjarska; Gang Wang; Silvio Wuschko; David Bumcrot; Victor Koteliansky; Stefan Limmer; Muthiah Manoharan; Hans-Peter Vornlocher
Journal:  Nature       Date:  2004-11-11       Impact factor: 49.962

7.  A High-Throughput Method for Direct Detection of Therapeutic Oligonucleotide-Induced Gene Silencing In Vivo.

Authors:  Andrew H Coles; Maire F Osborn; Julia F Alterman; Anton A Turanov; Bruno M D C Godinho; Lori Kennington; Kathryn Chase; Neil Aronin; Anastasia Khvorova
Journal:  Nucleic Acid Ther       Date:  2015-11-23       Impact factor: 5.486

8.  Secondary Release of Exosomes From Astrocytes Contributes to the Increase in Neural Plasticity and Improvement of Functional Recovery After Stroke in Rats Treated With Exosomes Harvested From MicroRNA 133b-Overexpressing Multipotent Mesenchymal Stromal Cells.

Authors:  Hongqi Xin; Fengjie Wang; Yanfeng Li; Qing-E Lu; Wing Lee Cheung; Yi Zhang; Zheng Gang Zhang; Michael Chopp
Journal:  Cell Transplant       Date:  2016-09-26       Impact factor: 4.064

9.  Safety and efficacy of RNAi therapy for transthyretin amyloidosis.

Authors:  Teresa Coelho; David Adams; Ana Silva; Pierre Lozeron; Philip N Hawkins; Timothy Mant; Javier Perez; Joseph Chiesa; Steve Warrington; Elizabeth Tranter; Malathy Munisamy; Rick Falzone; Jamie Harrop; Jeffrey Cehelsky; Brian R Bettencourt; Mary Geissler; James S Butler; Alfica Sehgal; Rachel E Meyers; Qingmin Chen; Todd Borland; Renta M Hutabarat; Valerie A Clausen; Rene Alvarez; Kevin Fitzgerald; Christina Gamba-Vitalo; Saraswathy V Nochur; Akshay K Vaishnaw; Dinah W Y Sah; Jared A Gollob; Ole B Suhr
Journal:  N Engl J Med       Date:  2013-08-29       Impact factor: 91.245

10.  Carrier-free cellular uptake and the gene-silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group.

Authors:  Natalya S Petrova; Ivan V Chernikov; Mariya I Meschaninova; Iiya S Dovydenko; Aliya G Venyaminova; Marina A Zenkova; Valentin V Vlassov; Elena L Chernolovskaya
Journal:  Nucleic Acids Res       Date:  2011-11-10       Impact factor: 16.971

View more
  18 in total

Review 1.  Advances in therapeutic applications of extracellular vesicles.

Authors:  Oscar P B Wiklander; Meadhbh Á Brennan; Jan Lötvall; Xandra O Breakefield; Samir El Andaloussi
Journal:  Sci Transl Med       Date:  2019-05-15       Impact factor: 17.956

2.  Immune Checkpoint Inhibition in GBM Primed with Radiation by Engineered Extracellular Vesicles.

Authors:  Tian Tian; Ruyu Liang; Gulsah Erel-Akbaba; Lorenzo Saad; Pierre J Obeid; Jun Gao; E Antonio Chiocca; Ralph Weissleder; Bakhos A Tannous
Journal:  ACS Nano       Date:  2022-01-31       Impact factor: 18.027

3.  Biomimetic nanovesicle design for cardiac tissue repair.

Authors:  Sruti Bheri; Jessica R Hoffman; Hyun-Ji Park; Michael E Davis
Journal:  Nanomedicine (Lond)       Date:  2020-08-05       Impact factor: 5.307

Review 4.  Aptamers as Modular Components of Therapeutic Nucleic Acid Nanotechnology.

Authors:  Martin Panigaj; M Brittany Johnson; Weina Ke; Jessica McMillan; Ekaterina A Goncharova; Morgan Chandler; Kirill A Afonin
Journal:  ACS Nano       Date:  2019-11-05       Impact factor: 15.881

5.  Enhanced Loading of Functional miRNA Cargo via pH Gradient Modification of Extracellular Vesicles.

Authors:  Anjana Jeyaram; Tek N Lamichhane; Sheng Wang; Lin Zou; Eshan Dahal; Stephanie M Kronstadt; Daniel Levy; Babita Parajuli; Daphne R Knudsen; Wei Chao; Steven M Jay
Journal:  Mol Ther       Date:  2019-12-24       Impact factor: 11.454

6.  A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties.

Authors:  Kevin Dooley; Russell E McConnell; Ke Xu; Nuruddeen D Lewis; Sonya Haupt; Madeleine R Youniss; Shelly Martin; Chang Ling Sia; Christine McCoy; Raymond J Moniz; Olga Burenkova; Jorge Sanchez-Salazar; Su Chul Jang; Bryan Choi; Rane A Harrison; Damian Houde; Dalia Burzyn; Charan Leng; Katherine Kirwin; Nikki L Ross; Jonathan D Finn; Leonid Gaidukov; Kyriakos D Economides; Scott Estes; James E Thornton; John D Kulman; Sriram Sathyanarayanan; Douglas E Williams
Journal:  Mol Ther       Date:  2021-01-21       Impact factor: 11.454

Review 7.  RNA delivery by extracellular vesicles in mammalian cells and its applications.

Authors:  Killian O'Brien; Koen Breyne; Stefano Ughetto; Louise C Laurent; Xandra O Breakefield
Journal:  Nat Rev Mol Cell Biol       Date:  2020-05-26       Impact factor: 94.444

Review 8.  Extracellular vesicle-based Nanotherapeutics: Emerging frontiers in anti-inflammatory therapy.

Authors:  Tao-Tao Tang; Bin Wang; Lin-Li Lv; Bi-Cheng Liu
Journal:  Theranostics       Date:  2020-07-09       Impact factor: 11.556

Review 9.  Native and bioengineered extracellular vesicles for cardiovascular therapeutics.

Authors:  Ricardo Cerqueira de Abreu; Hugo Fernandes; Paula A da Costa Martins; Susmita Sahoo; Costanza Emanueli; Lino Ferreira
Journal:  Nat Rev Cardiol       Date:  2020-06-01       Impact factor: 32.419

Review 10.  Advances in oligonucleotide drug delivery.

Authors:  Thomas C Roberts; Robert Langer; Matthew J A Wood
Journal:  Nat Rev Drug Discov       Date:  2020-08-11       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.